Areteia Therapeutics

The company's primary product is an investigational drug called dexpramipexole. This drug is a first-of-its-kind oral medication that inhibits the maturation of eosinophils, a type of white blood cell that contributes to the inflammation and damage in the lungs of asthma patients. Dexpramipexole has shown promising results in clinical trials, reducing eosinophils in blood and inflamed tissue, and potentially becoming the first oral treatment approved for eosinophilic asthma.

Areteia Therapeutics operates in the global healthcare market, serving a large patient population. Asthma affects 250 million people worldwide and causes 500,000 deaths per year. In the U.S. alone, asthma results in approximately 6 million doctor visits and 1.6 million emergency department visits annually. The company's business model revolves around addressing this significant unmet need in asthma treatment, particularly for the estimated 3 million U.S. and E.U. patients living with severe eosinophilic asthma.

The company generates revenue through the development and potential sale of its innovative drug. Given the high prevalence and severity of asthma, particularly eosinophilic asthma, the market potential for a successful treatment is substantial.